McMaster Textbook of Internal Medicine

Biosimilar drugs in Canada

2016-06-14

John Marshall

Do you use biosimilar drugs in Canada?

John Marshall: Canada is in a unique situation globally. Currently, as of May 2016, biosimilar infliximab is approved in Canada but not for the indication of inflammatory bowel disease (IBD), so our IBD clinics have not had exposure yet to biosimilars. I do not doubt this is going to change. There are clinical trials underway specifically in IBD and I suspect our regulatory agencies will assess those new data and give a broader indication. But biosimilars are in Canada, certainly for other indications, in rheumatology, for example.

See also

Gluten-free diet for the healthy population One of the recent dietary fads popular among healthy people has been the gluten-free diet. Should we advise against it? Should patients receive a medical warning?
Changing approaches to inflammatory bowel disease management A lecture by Prof. John Marshall, from McMaster University, Canada, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2016.
New therapies for inflammatory bowel disease What new therapies for inflammatory bowel disease can we expect in the near future?
Thoughts on biosimilar drugs What is your opinion on biosimilar drugs? Are they comparable to monoclonal antibodies?

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.